| Niharika Mehta, MD | |
|
695 East 16th Street , Suite E, Berwick, PA 18603 | |
| (570) 759-1830 | |
| (570) 759-1746 |
| Full Name | Niharika Mehta |
|---|---|
| Gender | Female |
| Speciality | Obstetrics & Gynecology |
| Location | 695 East 16th Street , Suite E, Berwick, Pennsylvania |
| Accepts Medicare Assignments | Does not participate in Medicare Program. She may not accept medicare assignment. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1861586497 | NPI | - | NPPES |
| 0009797340002 | Medicaid | PA |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 207V00000X | Obstetrics & Gynecology | MD031377 (Pennsylvania) | Primary |
| Mailing Address | Practice Location Address |
|---|---|
| Niharika Mehta, MD 695 East 16th Street , Suite E, Berwick, PA 18603 Ph: (570) 759-1830 | Niharika Mehta, MD 695 East 16th Street , Suite E, Berwick, PA 18603 Ph: (570) 759-1830 |
News Archive
Northwestern Medicine recently launched a multidisciplinary center dedicated to the comprehensive treatment of patients battling Huntington's disease. The new center will focus on both patient care and research of the inherited disease that causes the progressive breakdown of nerve cells in the brain.
In this post in the Results for Development Institute's "Center for Global Health R&D Policy Assessment" blog, Project Director Jean Arkedis and Program Associate Edith Han interview Megumi Gordon, deputy director for malaria at the Clinton Health Access Initiative (CHAI), "to take an exclusive look into the Affordable Medicines Facility for Malaria (AMFm) and its innovative mechanism to increase access to antimalarials."
Autifony Therapeutics Limited ("Autifony"), which is pioneering the development of novel pharmaceutical treatments for hearing disorders, today announced that it has been awarded funding of £2.2 million towards a Phase IIa clinical trial in tinnitus patients with its lead compound AUT00063, by the UK's innovation agency, the Technology Strategy Board.
Taro Pharmaceutical Industries Ltd. reported today that it has received final approval from the U.S. Food and Drug Administration ("FDA") for its Abbreviated New Drug Application ("ANDA") for cetirizine hydrochloride oral solution, 1 mg / 1 mL ("Cetirizine Oral Solution").
Immune system cells recruited by cancers to help them grow and spread could be 're-educated' to attack the tumours instead of aiding them, Cancer Research UK scientists announced at the National Cancer Research Institute (NCRI) Conference in Birmingham today (Wednesday).
› Verified 5 days ago